Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2015-02-13
Target enrollment:
Participant gender:
Summary
To estimate the progression free survival for subjects treated with panitumumab in
combination with a chemotherapy regimen of oxaliplatin, 5-Fluorouracil (5-FU) and leucovorin
(FOLFOX) as first-line chemotherapy regimen for subjects with metastatic colorectal cancer
with WT (wild type) KRAS according to the IGFRp (protein receptor insulin growth factor) and
MMP-7 (Matrilysin) expression.
Phase:
Phase 2
Details
Lead Sponsor:
Grupo Espanol Multidisciplinario del Cancer Digestivo